Related Experiment Video

Updated: Oct 6, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism

T V Wade1, D S Rothblat, J S Schneider

  • 1Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, JAH 521, Philadelphia, PA 19107, USA.

Brain Research
|June 26, 2001
PubMed

Insights

Dopamine D3 receptor density normalized in cats recovering from parkinsonism. This normalization correlated with symptom reduction, suggesting a key role for D3 receptors in the recovery process.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Parkinsonism is a neurodegenerative disorder characterized by motor deficits.
  • The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model in cats mimics key features of Parkinson's disease.
  • Dopamine D3 receptors are implicated in motor control and reward pathways.

Purpose of the Study:

  • To investigate the role of striatal dopamine D3 receptors in MPTP-induced parkinsonism and recovery.
  • To correlate changes in D3 receptor density and mRNA expression with behavioral recovery.

Main Methods:

  • Quantitative receptor autoradiography to measure D3 receptor density.
  • Reverse transcriptase-polymerase chain reaction to assess D3 receptor mRNA expression.
  • Behavioral assessment of parkinsonian signs in cats.

Main Results:

  • Symptomatic cats showed significantly decreased striatal D3 receptor density in the caudate nucleus, nucleus accumbens, and islands of Calleja.
  • D3 receptor density returned to normal levels in recovered cats.
  • D3 receptor mRNA expression was elevated in symptomatic cats and further increased in recovered cats.

Conclusions:

  • Normalization of striatal D3 receptor density is associated with the reduction of parkinsonian signs.
  • Altered D3 receptor expression, particularly mRNA levels, may be crucial for the recovery process in this parkinsonism model.
  • Dopamine D3 receptors represent a potential therapeutic target for promoting recovery from parkinsonism.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...